Daily Market Alert

    Strong Buy Stocks for Thursday, November 19, 2026: Five Names Riding Wednesday's Analyst Upgrades

    Thursday, November 19, 2026

    These are the five stocks to watch heading into Thursday, November 19, 2026. Each received a bullish rating change or new coverage on Wednesday, November 18. Stocks fell for a fourth straight session on Tuesday, November 17, as AI stocks led broad losses. The S&P 500 dropped 76.06 points, or 1%, to 7,340.53, its lowest close since July 29. The Dow Jones Industrial Average fell 848.75 points, or 1.6%, to 50,759.42, and the Nasdaq Composite slipped 181.37 points, or 0.7%, to 24,328.38. After the close on November 17, Nvidia reported revenue of $115.84 billion and adjusted EPS of $2.68, both above estimates. The S&P 500 was up 0.2% around 10 a.m. ET on November 18. Walmart reports before the open on November 19, and Anthropic's initial public offering is expected on November 19.

    The five ideas below span beverages, supply chain software, rare earth materials, solar infrastructure, and health insurance. Editorial notes only, not investment advice.

    πŸ“’ Sponsor Slot β€” rotating content will appear here

    Coca-Cola (KO) – Wolfe Research Initiates the Beverage Leader as a Top Pick

    Wolfe Research analyst Margaret-May Binshtok started coverage of Coca-Cola at Outperform with a $110.00 target. Wolfe named it a top pick, calling it "the one large beverage name growing volume without giving up price, with the best-positioned portfolio for the health shift." In our view, a defensive compounder with pricing power fits a market rattled by technology volatility.

    Shares traded near $97.92 during Wednesday's session, down about 0.9%, giving Coca-Cola a market capitalization near $421.22 billion. The stock sits near the top of its 52-week range of $67.27 to $100.56, with a trailing P/E of about 28.8 and a dividend yield near 2%.

    Consensus reads strong buy, with 14 of 15 tracked firms bullish and none bearish. The average target of $98.53 sits less than 1% above the price, so Wolfe's target, about 12.3% higher, better reflects the bull case. TD Cowen's Robert Moskow raised his target to $112.00 from $104.00 on November 17.

    Risks: Shares trade near a 52-week high at a premium multiple. Consumer pressure on volumes remains a factor to monitor.

    Manhattan Associates (MANH) – JPMorgan Initiates the Supply Chain Software Provider

    JPMorgan analyst Alexei Gogolev initiated Manhattan Associates at Overweight with a $308.00 target. He wrote that "early-stage cloud migration can drive meaningful growth reacceleration alongside continued margin expansion." Only about 25% of the installed base has moved to the cloud. In our view, the low cloud conversion rate gives the growth story a long runway.

    Shares traded near $252.87 during Wednesday's session, up about 1.1%, giving Manhattan Associates a market capitalization near $14.68 billion. The 52-week range runs from $119.06 to $263.47, and the trailing P/E is about 71.

    Consensus reads strong buy, with 8 of 9 tracked firms bullish and none bearish. The average target of $261.67 implies about 3.5% upside, while JPMorgan's target implies about 21.8%. Citi's George Kurosawa raised his target to $280.00 from $260.00 on October 28.

    Risks: JPMorgan itself acknowledged a premium valuation, and the stock has gained about 83% over six months. DA Davidson's Clark Wright rates it Neutral at $230.00, and cloud migration execution remains a factor to monitor.

    MP Materials (MP) – Needham Resumes the Rare Earth Producer at Buy

    Needham resumed coverage of MP Materials at Buy with a $48.00 target. The firm said MP is in "the third or fourth inning of a multi-year transformation" into a vertically integrated rare earth and magnet supplier. It cited government support and supply deals with General Motors and Apple. In our view, the call offers a more measured entry point after a steep decline.

    Shares traded near $36.26 during Wednesday's session, up about 4.0%, giving MP Materials a market capitalization near $6.46 billion. The stock trades well below its 52-week high, within a range of $31.90 to $76.80. The P/E is not meaningful because of trailing losses.

    Consensus reads strong buy, with all 11 tracked firms bullish. The average target of $74.36 looks stale relative to recent cuts, so Needham's target, about 32.4% above the price, is the more grounded reference. Barclays' Richard Garchitorena kept an Overweight rating but cut his target to $54.00 from $65.00 on November 9.

    Risks: Needham's target sits well below the $81.00 it set in June. Management has said the full earnings power of its magnet segment should become visible in 2028, so the timing of new capacity remains a factor to monitor.

    SOLV Energy (MWH) – UBS Upgrades the Solar Infrastructure Contractor

    UBS analyst Jon Windham upgraded SOLV Energy to Buy from Neutral while lowering his target to $37.00 from $50.00. He argued "the market is underappreciating several key tailwinds" amid uncertainty around data center demand and higher interest rates. UBS noted a third-quarter backlog of $9.2 billion, up 37% from a year earlier, and sees 19% annual EBITDA growth through 2028. In our view, the backlog provides solid revenue visibility for a project-based contractor.

    Shares traded near $27.39 during Wednesday's session, up about 0.5%, giving SOLV a market capitalization near $3.39 billion. The 52-week range spans $20.30 to $48.40, and the trailing P/E is about 46.

    Consensus reads strong buy, with 7 of 8 tracked firms bullish and none bearish. The average target of $39.75 implies about 45.1% upside, while UBS's target implies about 35.1%. TD Cowen's Marc Bianchi raised his target to $37.00 from $35.00 on November 16.

    Risks: The lower UBS target signals reduced expectations. Data center demand, interest rates, and project timing remain factors to monitor.

    Elevance Health (ELV) – Argus Upgrades the Health Insurer Despite a Sector Selloff

    Argus analyst David Toung upgraded Elevance Health to Buy from Hold with a $510.00 target. Argus expects stronger EPS growth in 2027 as the company raises Medicare Advantage premiums, seeks Medicaid rate adjustments, and exits unprofitable markets. In our view, the upgrade frames the sector selloff as a possible opportunity, though the regulatory overhang is real.

    Shares traded near $403.47 during Wednesday's session, down about 7.0%, giving Elevance a market capitalization near $87.17 billion. Insurers fell after a November 16 federal proposal known as CRUSH that would widen Medicare Advantage audits. The 52-week range runs from $273.71 to $450.69, and the trailing P/E is about 17.2.

    Consensus reads buy, with 13 of 18 tracked firms bullish and 1 bearish. The average target of $457.50 implies about 13.4% upside, while Argus's target implies about 26.4%. UBS's A.J. Rice raised his target to $523.00 from $460.00 on October 22.

    Risks: The CRUSH proposal could extrapolate audit findings back to payment year 2018, and comments close January 19, 2027. Mizuho listed Elevance among exposed insurers, which remains a factor to monitor.

    Found this helpful? Share it with others.

    Our Flagship Publication

    Discover Great Companies Trading at a Discount

    Join Behind the Markets